HCM News and Press, HUTCHMED (China) Limited From 01/18/23

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 18, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM: HCM; HKEX:13) today announces, following negotiations with the China National Healthcare Security Administration (“NHSA”), ORPATHYS...

Hutchmed (China) ( NASDAQ: HCM ) said it completed patient enrollment in a phase 3 trial of sovleplenib to treat adult patients with primary immune thrombocytopenia (ITP) in China. The study called ESLIM-01, which started in October 2021, has enrolled 188 patients and is...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Jan. 03, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that it has completed patient enrollment of ESLIM-01, a pivotal Phase III clinical trial of s...

— Company plans to complete rolling submission to the U.S. in the first half of 2023, followed by filings in Europe and Japan — — NDA is supported by global Phase III FRESCO-2 study conducted in the U.S., Europe, Japan and Australia — — FRESCO-2 ...

Acquisition to bring germline and somatic testing, cell-free DNA-based (liquid biopsy), and tissue-genomic profiling onto a single platform Cancer genomics testing is now standard practice for cancer care and has shown to be highly successful such as Foundation One (acquired by Roche), Grail ...

NEW YORK, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the presentations from its Depositary Receipts Virtual Investor Conference (“dbVIC”) held on November 16 th and 17 th are now available for online viewing. REGISTER NOW OR LOGIN AT : ...

Hutchmed (China) ( NASDAQ: HCM ) on Monday said that it will focus resources on its late-stage and registrational studies, while certain early-stage programs will not be prioritized for internal development. The company noted the decision was made following an evaluation...

Reprioritization accelerating path to profitability Evaluation of partnership opportunities for select late-stage assets HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/A...

Hutchmed (China) ( NASDAQ: HCM ) said its medicine fruquintinib met  one main goal but did not reach statistical significance in another in a phase 3 trial in Chinese patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. The study du...

— Results of dual primary endpoint study showed statistically significant and clinically meaningful benefit in progression-free survival, a primary endpoint — — Overall survival, the other primary endpoint, was not statistically significant — ...